Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452137 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 406
- Enrollment target
NCT03452137 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 406 participants.
The verdict
NCT03452137, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 406 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (SCCHN)
Interventions
- DRUG Placebo
- DRUG Atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2018-04-03 |
| Est. Completion | 2024-03-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03452137
The ClinicalTrials.gov registry entry for NCT03452137 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03452137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03452137 about?
NCT03452137 is a clinical study titled "A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck". This study will evaluate the efficacy and safety of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (SCCHN)
What is the current status of trial NCT03452137?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 406 participants. The study started on 2018-04-03. Estimated completion is 2024-03-06.
What interventions are being tested in trial NCT03452137?
The interventions under investigation include: Placebo (DRUG), Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT03452137?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.